Symphony Financial Ltd. Co. Has $261,000 Position in CVS Health Co. (NYSE:CVS)

Symphony Financial Ltd. Co. lowered its stake in CVS Health Co. (NYSE:CVS) by 14.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,275 shares of the pharmacy operator’s stock after selling 554 shares during the period. Symphony Financial Ltd. Co.’s holdings in CVS Health were worth $261,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Riverpoint Wealth Management Holdings LLC acquired a new position in CVS Health in the 4th quarter worth about $218,000. Canoe Financial LP grew its holdings in shares of CVS Health by 95.1% during the fourth quarter. Canoe Financial LP now owns 1,762,629 shares of the pharmacy operator’s stock worth $139,177,000 after purchasing an additional 859,134 shares during the last quarter. Meritage Portfolio Management raised its holdings in CVS Health by 30.6% in the 4th quarter. Meritage Portfolio Management now owns 66,322 shares of the pharmacy operator’s stock valued at $5,237,000 after buying an additional 15,548 shares during the last quarter. Steph & Co. raised its holdings in CVS Health by 192.0% in the 1st quarter. Steph & Co. now owns 438 shares of the pharmacy operator’s stock valued at $35,000 after buying an additional 288 shares during the last quarter. Finally, Forum Financial Management LP raised its holdings in CVS Health by 19.4% in the 4th quarter. Forum Financial Management LP now owns 17,856 shares of the pharmacy operator’s stock valued at $1,410,000 after buying an additional 2,901 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Edward J. Ludwig acquired 1,000 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was bought at an average price of $53.88 per share, with a total value of $53,880.00. Following the completion of the acquisition, the director now owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.24% of the company’s stock.

CVS Health Stock Performance

CVS traded up $0.70 during trading hours on Friday, hitting $59.06. The stock had a trading volume of 14,343,538 shares, compared to its average volume of 11,322,786. The company’s fifty day simple moving average is $59.56 and its 200 day simple moving average is $70.17. CVS Health Co. has a 1 year low of $52.77 and a 1 year high of $83.25. The stock has a market cap of $74.14 billion, a PE ratio of 10.38, a price-to-earnings-growth ratio of 0.56 and a beta of 0.53. The company has a quick ratio of 0.61, a current ratio of 0.81 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The company had revenue of $88.44 billion for the quarter, compared to analysts’ expectations of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.20 EPS. Equities analysts anticipate that CVS Health Co. will post 7.02 earnings per share for the current year.

Analyst Ratings Changes

CVS has been the subject of a number of research reports. Bank of America dropped their price objective on shares of CVS Health from $95.00 to $77.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Barclays decreased their target price on shares of CVS Health from $78.00 to $63.00 and set an “equal weight” rating for the company in a research report on Thursday, May 2nd. Baird R W raised shares of CVS Health to a “hold” rating in a research report on Thursday, May 30th. Robert W. Baird initiated coverage on shares of CVS Health in a research report on Thursday, May 30th. They set a “neutral” rating and a $61.00 price objective for the company. Finally, Leerink Partnrs downgraded shares of CVS Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 1st. Eleven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $75.05.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.